Debut Plus

70

+0.64 +0.92%

17 Jul 2026

NSE Listed · Pharmaceuticals

ESM 1

Lyka Labs Ltd. (LYKALABS)

Volume: 6,009Avg Vol 1W: 2,927Avg Vol 1M: 7,63952W Range:44.1121.44
Market Cap₹251 Cr
Current Price₹70
Previous Close₹69.36
High / Low (52w)₹121.44 / ₹44.1
Volume6,009
Avg Vol (1W)2,927
Avg Vol (1M)7,639
Stock P/E45.07
Book Value₹25.68
Dividend Yield0%
ROE-10.86%
ROA-5.98%
Revenue (TTM)
Revenue Growth24.55%
Profit Margin-7.82%
Total Debt₹18 Cr
Shares Outstanding4 Cr
Face Value₹10
EPS (TTM)₹0
P/B2.7
Debt / Equity0.55
50 DMA₹70.51
200 DMA₹61.84
Day change+0.92%
SurveillanceESM 1 (as of 2026-07-17)
Price Chart
70 17.04% · 1Y
101453.9L
2025-11-21
2026-07-16

20-day avg volume: 7K shares

Pros
  • Company is almost debt-free.
  • Revenue grew 25% YoY.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹30 Cr₹41 Cr₹34 Cr₹33 Cr₹33 Cr₹37 Cr₹31 Cr₹28 Cr
EBITDA₹3 Cr₹3 Cr₹4 Cr₹3 Cr₹2 Cr₹-4 Cr₹1 Cr₹-8 Cr
Net Profit₹1 Cr₹2 Cr₹3 Cr₹2 Cr₹1 Cr₹-3 Cr₹0 Cr₹-8 Cr
EPS
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹62 Cr₹73 Cr₹65 Cr₹88 Cr₹196 Cr₹96 Cr₹113 Cr₹141 Cr
EBITDA₹-13 Cr₹-7 Cr₹-9 Cr₹13 Cr₹86 Cr₹6 Cr₹4 Cr₹13 Cr
Net Profit₹-17 Cr₹-6 Cr₹-61 Cr₹-12 Cr₹39 Cr₹-13 Cr₹-3 Cr₹8 Cr
EPS-6.69-1.97-21.29-4.0313.59-4.63-0.792.22
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹229 Cr₹216 Cr₹200 Cr₹190 Cr₹186 Cr₹152 Cr₹157 Cr₹176 Cr
Total Liabilities₹176 Cr₹170 Cr₹215 Cr₹215 Cr₹172 Cr₹106 Cr₹88 Cr₹73 Cr
Equity₹53 Cr₹46 Cr₹-15 Cr₹-25 Cr₹13 Cr₹46 Cr₹68 Cr₹104 Cr
Total Debt
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹11 Cr₹27 Cr₹5 Cr₹10 Cr₹80 Cr₹9 Cr₹3 Cr₹5 Cr
Investing₹-3 Cr₹-4 Cr₹0 Cr₹0 Cr₹-6 Cr₹7 Cr₹-9 Cr₹-12 Cr
Financing₹-10 Cr₹-23 Cr₹3 Cr₹-12 Cr₹-63 Cr₹-22 Cr₹2 Cr₹5 Cr
Free Cash Flow₹11 Cr₹27 Cr₹5 Cr₹10 Cr₹80 Cr₹9 Cr₹3 Cr₹5 Cr
Shareholding
Promoter 58.16% Institutions 0.95% Public 40.88%
Efficiency & Working Capital
ROCE-6%
Interest Coverage5.9
Dividend Payout
Debtor Days114 d
Inventory Days33 d
Payable Days39 d
Cash Conversion Cycle107 d
Working Capital Days146 d
Shareholding Details

As of 2026-03-31

Promoter58.2%
FII0.3%
DII0.7%
Institutions1%
Public40.9%
Promoter Pledge0%
No. of Shareholders26,727
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Apr 2024Apr 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters54.8%54.8%58.1%58.1%58.1%58.1%58.1%58.2%58.2%58.2%58.2%58.2%
FIIs0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.2%0.3%
DIIs0.4%0.9%0.8%0.8%0.8%0.7%0.7%0.7%0.7%0.7%0.7%0.7%
Public44.6%44.1%40.9%40.9%41%41.1%41.1%40.9%41%41%41%40.9%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders26,42225,71725,69925,69925,71628,94329,09928,47228,18927,74327,15526,727
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Ipca Laboratories LimitedShareholding of Promoter and Promoter Group41%1.46 Cr
Kunal Narendra GandhiShareholding of Promoter and Promoter Group9.8%34,93,629
Nehal Narendra GandhiShareholding of Promoter and Promoter Group3.3%11,62,371
Enai Trading And Investment Pvt. LtdShareholding of Promoter and Promoter Group2.8%10,00,000
Thermo Capital Private LimitedPublic Shareholding2%7,11,618
Pranay GodhaShareholding of Promoter and Promoter Group0.8%3,00,000
Alisha Kunal GandhiShareholding of Promoter and Promoter Group0.1%45,000
Sweta ShahShareholding of Promoter and Promoter Group0.1%41,000
Ushma Ronak ShahShareholding of Promoter and Promoter Group0.1%33,000
Lyka Generics LimitedShareholding of Promoter and Promoter Group0.1%20,000
Neetu GodhaShareholding of Promoter and Promoter Group0%10,000
Usha GodhaShareholding of Promoter and Promoter Group0%10,686
Premchand GodhaShareholding of Promoter and Promoter Group0%10,900
Bhawna GodhaShareholding of Promoter and Promoter Group0%6,000
Hiralaxmi Multitrade Private LimitedShareholding of Promoter and Promoter Group0%708
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Bhawna Godha00%2026-03-31
Neetu Godha00%2026-03-31
Usha Godha00%2026-03-31
Premchand Godha00%2026-03-31
Ushma Ronak Shah00%2026-03-31
Sweta Shah00%2026-03-31
Alisha Kunal Gandhi00%2026-03-31
Pranay Godha00%2026-03-31
Nehal Narendra Gandhi00%2026-03-31
Kunal Narendra Gandhi00%2026-03-31
Hiralaxmi Multitrade Private Limited00%2026-03-31
Lyka Generics Limited00%2026-03-31
Board of Directors
NameDesignationYear
KUNAL NARENDRA GANDHIManaging Director & Chief Executive Officer2025
Yogesh B ShahWhole Time Director & Chief Financial Officer2025
Dhara P. ShahNon Executive & Independent Director2025
Babulal JainChairman & Independent Director2025
Prashant GodhaNon Executive Director2025
Shashil MendonsaNon Executive Director2025
Archana YadavNon Executive & Independent Director2025
Neeraj GolasNon Executive & Independent Director2025
Shailendra Kumar AgrawalCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceutical products/Pharma rela₹0 Cr
Segments — Geography
RegionRevenueShare
Domestic₹85 Cr65.4%
Exports₹45 Cr34.6%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10483636
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025500910138
20253000960
2025000011
Insider / Designated-Person Trades

30 recent disclosure(s)

Kunal N GandhiAcquisition · 1,262
Kunal N GandhiAcquisition · 12,914
Kunal N GandhiAcquisition · 1,262
Kunal N GandhiAcquisition · 12,914
Enai Trading and Investment Pvt.Acquisition · 11,312
Alisha GandhiAcquisition · 5,000
Substantial Acquisitions (SAST)

8 disclosure(s)

Inter-se Transfer25/06/2025 · 74,000
Inter-se Transfer25/06/2025 · 74,000
Inter-se Transfer24/03/2025 · 10,68,629
Conv. of Warrants16/04/2024 · 26,00,000
Market22/09/2023 · 24,839
Market22/09/2023 · 24,839
Company Information
Incorporated1976
ChairmanBabulal Jain
AuditorD Kothary & Co
🌐 www.lykalabs.com

📍 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search